Background: West Virginia (WV) residents are at high risk for polypharmacy given its considerable chronic disease burdens. Objective: To evaluate the prevalence, correlates, outcomes, and geographic variations of polypharmacy among WV Medicaid beneficiaries. Methods: In this cross-sectional study, we analyzed 2009-2010 WV Medicaid feefor-service (FFS) claims data for adults aged 18-64 (N=37,570). We defined polypharmacy as simultaneous use of drugs from five or more different drug classes on a daily basis for at least 60 consecutive days in one year. Multilevel logistic regression was used to explore the individual-and county-level factors associated with polypharmacy. Its relationship with healthcare utilization was assessed using negative binomial regression and logistic regression. The univariate local indicators of spatial association method was applied to explore spatial patterns of polypharmacy in WV. Results: The prevalence of polypharmacy among WV Medicaid beneficiaries was 44.6%. High-high clusters of polypharmacy were identified in southern WV, indicating counties with above-average prevalence surrounded by counties with above-average prevalence. Polypharmacy was associated with being older, female, eligible for Medicaid due to cash assistance or medical eligibility, having any chronic conditions or more chronic conditions, and living in a county with lower levels of education. Polypharmacy was associated with more hospitalizations, emergency department visits, and outpatient visits, as well as higher non-drug medical expenditures. Conclusions: Polypharmacy was prevalent among WV Medicaid beneficiaries and was associated with substantial healthcare utilization and expenditures. The clustering of high prevalence of polypharmacy in southern WV may suggest targeted strategies to reduce polypharmacy burden in these areas.
Introduction
Polypharmacy is conventionally regarded as the concurrent use of multiple medications. It is associated with negative health outcomes, including drug-drug interactions, adverse drug events, decreased medication adherence, increased risk of mortality, and increased health care use and costs. 1, 2 Polypharmacy research has primarily focused on the elderly population, whereas knowledge about the prevalence of polypharmacy and related issues in the general adult population is still limited. However, recent studies have suggested that multimorbidity and polypharmacy are no longer merely issues for the elderly. The prevalence of multimorbidity among those who were 45 to 64 years old and participated in the National Health Interview Survey increased from 24 .5% in 2004 to 28 .1% in 2010. 3 Another study examining the 2009 Medical Expenditure Panel Survey found that the prevalence of multimorbidity was similar in those aged 50 to 64 years (8.2%) and those ≥65 years old (9%). There was a relationship between multimorbidity and polypharmacy in both age groups. 4 Kanto et al 5 also found that 15% of those who were 40 to 64 years old in 2011-2012 had polypharmacy, which was a significant increase from the 1999-2000 period (10%). 5 On the other hand, there is no firm consensus on the definition of polypharmacy. A narrative review of polypharmacy 717017A OPXXX10.1177/1060028017717017Annals of PharmacotherapyFeng et al research-article2017 among elderly individuals identified 24 distinct definitions. 6 These definitions range from concurrent use of 5 or more drugs, to use of at least 1 inappropriate drug, to use of medications that do not match a patient's diagnosis. 6 Even when studies used a certain number of drugs to define polypharmacy, the numbers varied from 2 drugs 7 to more than 1 SD above the average number of drugs in a specific population. 8 In addition, the duration of concomitant drug use also varied ranging from 30 days to 90 days. 9, 10 This inconsistency in the definition results in challenges for the measurement of polypharmacy.
In addition, West Virginia (WV) residents are at particularly high risk for polypharmacy because it has one of the highest chronic disease burdens in the United States. 11, 12 Yet, to our knowledge, there has been no systematic examination of this critical issue in WV, including in the Medicaid population of WV. Medicaid is a joint federal-state, public health insurance program in the United States that mainly covers low-income individuals with limited resources. Therefore, the purpose of this study was to estimate the prevalence of polypharmacy by integrating the definitions used in the literature and establishing a feasible approach for addressing this issue using administrative claims data. We also aimed to explore the factors associated with polypharmacy and to evaluate the health care use, health expenditures, and geographic variations of polypharmacy among WV Medicaid beneficiaries.
Methods

Study Design, Study Population, and Data Source
In this cross-sectional study, we analyzed WV Medicaid fee-for-service (FFS) claims data in 2009-2010. We included adults who were between 18 and 64 years old, alive during the study time, and continuously enrolled in WV Medicaid's FFS program in both 2009 and 2010. Those with dual Medicaid and Medicare eligibility and with private insurance were excluded from the study. Appendix A shows the flowchart for obtaining the final study population.
The main data source was the Medicaid Analytic eXtract (MAX) data system, which contains extensive person-level data on Medicaid beneficiaries and Medicaid health services. We extracted data for WV Medicaid FFS enrollees from the following MAX files: person summary file, which contains demographic and enrollment data; inpatient file, including hospital claims; prescription drug file with pharmacy claims; and other services file, which involves all types of services not included in the other 4 files. To assess county-level factors, we linked the county code of each Medicaid beneficiary with the Area Health Resources File as well as the Appalachian Regional Commission data reports. The study was approved by WV University's Institution Review Board.
Outcome Measures
Polypharmacy. Our definition of polypharmacy incorporated 3 important components of polypharmacy measures: number of drugs, simultaneous use, and duration of use. First, we chose to use a widely accepted, standard cutoff for clinically relevant polypharmacy: the concurrent use of 5 or more drugs from different drug classes. [13] [14] [15] Drugs were identified by the National Drug Codes and classified based on the methodology created in a previous study. 16 Second, among the 3 common measures of polypharmacy (cumulative, continuous, and simultaneous), we chose simultaneous polypharmacy because it gives a value in between the values of cumulative and continuous measures and can demonstrate subtle and transient changes in medications. 17 We defined simultaneous use as the sum of all drug classes used by 1 individual daily, which was developed based on the methodology of Fincke et al. 17 Finally, we chose a consecutive interval of at least 60 days in 1 year as 1 criterion for polypharmacy definition. To summarize, by our definition, polypharmacy was defined as simultaneous use of 5 or more drugs from different drug classes for a consecutive interval of at least 60 days in 1 year. To allow for an 80% medication adherence rate, we also allowed for a gap of 12 days within this interval. In other words, the individual with polypharmacy took 5 or more drugs from different drug classes per day for at least 60 days in 72 consecutive days in 2010.
Health Care Use and Expenditures. We examined 3 types of health care use in each individual in 2010: inpatient hospitalization, outpatient visits, and emergency department (ED) visits. Nondrug health care expenditures were assessed by summing up the expenditures from inpatient services, outpatient services, home health, laboratory/X-ray, and hospice for each eligible individual in 2010. The cost evaluation was from the payer's perspective.
Measurement of Independent Variables
We examined individual-and county-level factors associated with polypharmacy, which followed the constructs of the conceptual framework in the Andersen's Health Behavioral Model of Health Services Use. 18, 19 We measured the individual-level characteristics: (1) predisposing factors: age group and gender; (2) enabling factors: Medicaid pathway-to-eligibility indicators, including medical needs and cash assistance, and having private insurance or not; (3) need factors: number of chronic conditions and types of chronic conditions (physical conditions only, mental conditions only, none, or both). Chronic conditions were identified by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes in 2009. We utilized the strategic framework adopted by the US Department of Health and Human Services (DHHS) for research, policy, program, and practice 20 and also added some other major mental health conditions. The final list of chronic conditions included hypertension, congestive heart failure, coronary artery disease, cardiac arrhythmias, hyperlipidemia, stroke, arthritis, asthma, cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), diabetes, hepatitis, HIV, osteoporosis, dementia, depression, schizophrenia, substance abuse, anxiety or posttraumatic stress disorder, and bipolar disorder (Appendix B). Environmental characteristics were assessed by county-level factors, which included county-level metropolitan status, county-level economic status (distressed counties refer to the lowest 10% of the US counties), 21 county-level percentage of persons with less than a high school education in quartiles, and health professional shortage area for primary care doctors.
Statistical Analysis
We calculated polypharmacy rates for the entire final study population and for individuals with different types of chronic conditions. Descriptive statistics of other dependent and independent variables were calculated using means for continuous variables and frequencies and percentages for categorical variables. We assessed bivariate associations of polypharmacy and each factor using χ 2 tests for binary and categorical variables as well as the 2-tailed t-tests for continuous variables. To take into consideration potential clustering effects at the county level, we used a multilevel logistic regression model to assess the factors associated with polypharmacy. The association of polypharmacy with outpatient visits was evaluated using a negative binomial model. We utilized logistic regressions to assess the relationships between polypharmacy with inpatient visits and ED visits. The impact of polypharmacy on nondrug medical expenditures was assessed using a generalized linear model with log-link function and gamma distribution. We also used recycled predictions to estimate absolute expenditure differences between polypharmacy and nonpolypharmacy. 22 We used STATA 14 (StataCorp LP, College Station, TX) for data analyses.
Spatial Analysis
The aggregated county-level polypharmacy rates were displayed in choropleth maps. The univariate local indicators of spatial association (LISA) method 23 and global Moran's I statistics were applied to study the spatial variations of polypharmacy rates across WV. The univariate LISA method can help identify 4 types of spatial patterns: (1) low-low cluster, (2) high-high cluster, (3) low-high outlier, (4) high-low outlier. A high-high cluster indicates a county with an above-average prevalence surrounded by counties with above-average prevalence, whereas a low-low cluster refers to a county with a below-average rate surrounded by counties with below-average rates. The Queen contiguity weights matrix was used to define counties sharing a border or vertex/corner with a county's neighbors. For the univariate LISA statistics for each observation and cluster/outlier, the significance level was set at P <0.05. We used ArcGIS 10.4 (ESRI, Redlands, CA) for geo-mapping and GeoDa 1.8 software for the LISA method.
Results
Our analyses included a total of 37 570 WV Medicaid beneficiaries, whose characteristics are presented in Table 1 . The majority of participants were female (58.4%), middleaged (45-64 years old, 60.4%), eligible for Medicaid as a result of cash assistance (91.1%), and with 1 or more chronic conditions assessed in our study (79.8%). About half of them (51.5%) lived in nonmetropolitan areas, and 77.4% lived in primary care doctor shortage areas. The average number of drug classes taken per person per day was 3.9.
Based on our definition, 44.6% of adult Medicaid FFS beneficiaries in WV were classified as having polypharmacy. Among those with polypharmacy, the average number of drug classes taken per day was 6.7. The prevalence of polypharmacy varied among different chronic conditions, ranging from 43.3% to 85.4%. The top 10 conditions with the highest prevalence of polypharmacy were chronic kidney disease (85.4%), congestive heart failure (85.1%), coronary artery disease (80.5%), diabetes (74.9%), dementia (74.4%), stroke (73.1%), osteoporosis (71.5%), hyperlipidemia (69.8%), cardiac arrhythmias (69.2%), and COPD (69.1%). With the exception of dementia, these conditions were also highly prevalent generally among this nonelderly population. Patients with chronic kidney disease, congestive heart failure, coronary artery disease, diabetes, and stroke took at least 6 drug classes on average per day. The most prescribed drug classes at the individual level were analgesics (74.8%) and antibiotics (68.7%), followed, in descending order, by anticonvulsants (48.8%), antidepressants (48.4%), proton pump inhibitors (44.3%), bronchodilators (35.4%), statins (34.5%), anxiolytics (31.9%), antihistamines (29.5%), and angiotensin-converting enzyme inhibitors/angiotensinreceptor blockers (26.8%). Among those with polypharmacy, 85.3% and 76.9% were prescribed analgesics and antibiotics, respectively.
The county-level polypharmacy rates ranged from 31.2% to 54.4% ( Figure 1A) . The global Moran's I of the county-level polypharmacy rates in WV was 0.43 (P < 0.01), indicating a positive spatial autocorrelation (clustering patterns) of polypharmacy in WV. Accordingly, in the univariate LISA, a large and clear high-high cluster of polypharmacy was observed in southern WV ( Figure 1B) , which includes the counties of Boone, Fayette, Greenbrier, Lincoln, Logan, Monroe, Mingo, Nicholas, Summers, Raleigh, and Wyoming. These counties had above-average polypharmacy rates and were also surrounded by other counties with above-average polypharmacy rates. On the other hand, 2 smaller low-low clusters were found in northeastern WV, including Morgan and Berkeley counties. Table 2 displays the results of the multilevel logistic regression of polypharmacy. We found that being older, female, eligible for Medicaid as a result of cash assistance or medical eligibility, having any chronic condition or more chronic conditions, and living in a county with lower levels (4) high-low outlier (pink). A high-high cluster indicates a county with an above-average prevalence surrounded by counties with above-average prevalence, whereas a low-low cluster refers to a county with a below-average rate surrounded by counties with below-average rates. As shown in the figure, we identified a large and clear high-high cluster of polypharmacy in southern WV, which included 11 counties.
of education were associated with a higher likelihood of polypharmacy. Also, patients with physical conditions were more likely to have polypharmacy than those with mental conditions (adjusted odds ratio [AOR] = 1.98; 95% CI = 1.84, 2.14). Table 3 presents the relationships between polypharmacy, health care use, and nondrug expenditures. Those people with polypharmacy had 69% more outpatient visits than those without polypharmacy (P < 0.01). In addition, patients with polypharmacy were more likely to have ED visits (AOR = 1.18; 95% CI = 1.13-1.24) and inpatient visits (AOR = 1.78; 95% CI = 1.67-1.90) compared with those without polypharmacy. Polypharmacy was associated with $4494.36 more in nondrug medical expenditures than nonpolypharmacy (coefficient = 0.69; 95% CI = 0.64-0.74; P < 0.01).
Discussion
The current study made a unique contribution to the limited literature of polypharmacy research among adults younger than 65 years by estimating the prevalence of polypharmacy among Medicaid beneficiaries in WV. By integrating various measures of prescription drugs use-duration of use, simultaneous use, and number of drug classes, we observed that polypharmacy was highly prevalent (44.6%) among those <65 years old, which was even higher than the US average rate among adults >21 years of age in 2009 (25.5%) 4 and among the elderly population in 2010 (39.0%). 24 Despite our strict definition, we still found such a high prevalence in this population, suggesting a substantial burden of polypharmacy and related issues in WV. Because this is the first study of its kind in WV, we cannot suggest whether our study findings are consistent with those from the other literature. However, a previous study examining the region-level variations of polypharmacy in the United States also found that WV was located in the region with the highest prevalence of polypharmacy. 25 Not surprisingly, we found that adults with selected chronic conditions were more likely to have polypharmacy compared with those without these selected chronic conditions. WV also ranks among the top 10 states with the highest prevalence of many chronic conditions, such as cardiovascular diseases, diabetes, stroke, hypertension, cancer, COPD, arthritis, and kidney disease, as well as risk factors such as obesity, tobacco use, and physical inactivity, 11, 12 The results were adjusted by age groups, Medicaid eligibility pathway, sex, presence of chronic conditions, county-level metropolitan status, and county-level economic status. **P < 0.01; *0.01 ≤ P < 0.05.
which may partially explain the high burden of polypharmacy in WV. Furthermore, given the trend of increasing polypharmacy rates among American adults over the past 2 decades, 5, 24 it may be expected that the burden of polypharmacy in the WV Medicaid population has continued to increase following the period of our study.
Consistent with the previous literature, 16, 26 our study showed that polypharmacy was associated with substantial economic burden, including increased health care use and expenditures. Based on our results in 2010, on average, 1 Medicaid beneficiary with polypharmacy had $4494.36 more in nondrug medical expenditures. Since 2014, Medicaid coverage in WV has been expanded to include individuals aged between 19 and 65 years old with income limit at 133% of the federal poverty level. 27 Given the chronic disease burdens and high polypharmacy rates in this state, it is reasonable to expect more Medicaid beneficiaries with polypharmacy and multimorbidity, which may lead to an increase in health care use and expenditures. Therefore, actions to control the increasing trend of these issues are warranted in order to contain costs in the Medicaid program, which has limited resources and a tight budget.
To more deeply understand this issue in WV, our study further explored the county-level geographic variations of polypharmacy prevalence and identified a high-high cluster of polypharmacy in southern WV that included 11 counties. Almost all these 11 counties also had higher poverty rates and lower education levels than the state as a whole. 28 These counties also had significantly higher prevalence than the WV and US averages of the following health-related indicators: reported fair or poor general health, no leisure-time physical activity or exercise, obesity, hypertension, cardiovascular disease, diabetes, arthritis, and disability. 11 Also, we found that the most prescribed drug classes for West Virginians were analgesics and antibiotics. This is not surprising because WV has one of the highest prescription rates of opioids and outpatient antibiotics in the United States. 29, 30 These drugs require particular attention because of the high risk for inappropriate use and adverse drug events leading to harms. 31 Overall, our findings may be helpful for WV Medicaid policy makers to target "hot-spot" areas and "high-risk" drugs requiring close monitoring and regulations and to collaborate with local communities to develop and implement interventions to reduce the risk of polypharmacy and other relevant medication-related issues in the Medicaid population.
We also found that individual characteristics such as being older, being female, and having more chronic conditions were significantly correlated with polypharmacy, consistent with the previous literature. 2, 4, 5, 25 In particular, we found that polypharmacy was not only related to the number of chronic conditions, but also associated with different types of chronic conditions. We found that patients with physical conditions were more likely to have polypharmacy than those with mental conditions. This finding may be partially a result of our measurement of polypharmacy, which only assessed different drug classes but not within drug classes. Within-drug-class polypharmacy is not uncommon in mental condition management; therefore, our definition may to some extent underestimate polypharmacy burden in this population. Nevertheless, it is worthwhile for future research to further investigate the impacts of different types and combinations of chronic conditions on polypharmacy, inappropriate medication use, and medication regimen complexity. It is also interesting in our results that about 5% of the individuals without any chronic disease included in our study had polypharmacy, which may represent the population who used medications for chronic diseases not included in this study, acute diseases, disease prevention purposes, and/or unclear indications. Additionally, for county-level characteristics, we found that lower educational level was associated with polypharmacy, which was also reflected in the "hot spots" of polypharmacy identified in our spatial analysis. Further research may need to confirm the influence of individual educational level, patient knowledge about medications, and health literacy on polypharmacy, which may also suggest important targets for developing interventions to address these issues.
Several limitations to this study should be noted. First, the cross-sectional design of this study in 1 year made it difficult to infer causality. We did not measure the temporal relationship between polypharmacy and health care use or nondrug medical expenditures in this study, which warrants further research. Second, by our new definition, we only assessed polypharmacy from different drug classes but not within-drug-class polypharmacy. For instance, patients may take multiple antipsychotic drugs, but according to our definition, they are only considered to be taking 1 drug class. Third, our approach may not fully capture early refill issues or patients' real medication-taking behaviors. Fourth, because the data did not contain the accurate indications for the drug used or detailed clinical information, we cannot differentiate between appropriate and inappropriate polypharmacy. Therefore, the next step for this research will be to further explore inappropriate polypharmacy in this population. Finally, caution is required when generalizing the study findings. In particular, the impact of moving from FFS to managed care in WV Medicaid on polypharmacy is still not clear and warrants further research. But the approach for assessing the prevalence and geographic variations of polypharmacy established in this study may be applied to other populations or geographic regions by using claims data.
Conclusions
Polypharmacy was highly prevalent among WV Medicaid FFS beneficiaries and was associated with substantial health
